Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | TLR2 | O60603 | 2/20 | 0.37 |
| ▸ | PAOX | Q6QHF9 | 2/20 | 0.35 |
| ▸ | EPOR | P19235 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 3/20 | 0.35 |
| ▸ | CA2 | P00918 | 3/20 | 0.34 |
| ▸ | CHRNA1 | P02708 | 3/20 | 0.34 |
| ▸ | CHRNG | P07510 | 3/20 | 0.34 |
| ▸ | CHRNB1 | P11230 | 3/20 | 0.34 |
| ▸ | CHRND | Q07001 | 3/20 | 0.34 |
| ▸ | GABRR3 | A8MPY1 | 1/20 | 0.33 |
| ▸ | GABRP | O00591 | 1/20 | 0.33 |
| ▸ | GABRD | O14764 | 1/20 | 0.33 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.33 |
| ▸ | GABBR2 | O75899 | 1/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | THRB | P10828 | 1/20 | 0.33 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27160303 | 0.94 | TLR2 (0.41) | SMN1; SMN2KMT2AMEN1TLR2PAOX | |
| SCHEMBL22326246 | 0.92 | TLR2 (0.43) | SMN1; SMN2KMT2AMEN1TLR2PAOX | |
| SCHEMBL21806080 | 0.92 | PAOX (0.39) | SMN1; SMN2TLR2PAOXCHRNA1CHRNG | |
| SCHEMBL2330619 | 0.92 | PAOX (0.39) | SMN1; SMN2TLR2PAOXCHRNA1CHRNG | |
| SCHEMBL16039497 | 0.90 | CHRNA1 (0.38) | SMN1; SMN2TLR2PAOXCHRNA1CHRNG | |
| Hydrochloric Acid SCHEMBL17749233 | 0.90 | CHRNA1 (0.38) | SMN1; SMN2TLR2PAOXCHRNA1CHRNG | |
| SCHEMBL17873797 | 0.90 | PAOX (0.41) | SMN1; SMN2KMT2AMEN1TLR2PAOX | |
| SCHEMBL23884373 | 0.88 | PAOX (0.39) | SMN1; SMN2KMT2AMEN1TLR2PAOX | |
| SCHEMBL26923885 | 0.88 | SMN1; SMN2 (0.38) | SMN1; SMN2KMT2AMEN1TLR2PAOX | |
| SCHEMBL14740855 | 0.88 | SMN1; SMN2 (0.44) | SMN1; SMN2KMT2AMEN1TLR2EPOR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230078961-A1 | HMG-CoA Reductase Degradation Inducing Compound | UPPTHERA INC. (KR) | 2023-03-16 | — | — | US | disclosed |
| WO-2021201577-A1 | HMG-COA REDUCTASE DEGRADATION INDUCING COMPOUND | UPPTHERA (KR) | 2021-10-07 | — | — | WO | disclosed |
| EP-3455219-A1 | AMINE-LINKED C3-GLUTARIMIDE DEGRONIMERS FOR TARGET PROTEIN DEGRADATION | C4 Therapeutics, Inc. (US) | 2019-03-20 | — | — | EP | disclosed |
| US-20190076539-A1 | AMINE-LINKED C3-GLUTARIMIDE DEGRONIMERS FOR TARGET PROTEIN DEGRADATION | C4 Theraprutics, Inc. (US) | 2019-03-14 | — | — | US | disclosed |
| WO-2017197051-A1 | AMINE-LINKED C3-GLUTARIMIDE DEGRONIMERS FOR TARGET PROTEIN DEGRADATION | C4 THERAPEUTICS, INC. (US) | 2017-11-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190076539-A1 | AMINE-LINKED C3-GLUTARIMIDE DEGRONIMERS FOR TARGET PROTEIN DEGRADATION | GCGR, STUB1, GID4 | SMN1; SMN2 3654/4885KMT2A 2669/4885MEN1 213/4885 |
| US-20230078961-A1 | HMG-CoA Reductase Degradation Inducing Compound | HMGCR, HMGB2, LDLR | SMN1; SMN2 4532/4885KMT2A 2204/4885MEN1 3715/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.